1. Home
  2. ELUT vs PPCB Comparison

ELUT vs PPCB Comparison

Compare ELUT & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elutia Inc.

ELUT

Elutia Inc.

HOLD

Current Price

$0.70

Market Cap

25.2M

Sector

Health Care

ML Signal

HOLD

PPCB

Propanc Biopharma Inc.

N/A

Current Price

$0.76

Market Cap

20.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ELUT
PPCB
Founded
2015
2007
Country
United States
Australia
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.2M
20.4M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ELUT
PPCB
Price
$0.70
$0.76
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
242.1K
266.9K
Earning Date
11-06-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$21,746,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.08
N/A
52 Week Low
$0.58
$0.73
52 Week High
$4.84
$145.46

Technical Indicators

Market Signals
Indicator
ELUT
PPCB
Relative Strength Index (RSI) 44.43 N/A
Support Level $0.66 N/A
Resistance Level $0.72 N/A
Average True Range (ATR) 0.06 0.00
MACD 0.02 0.00
Stochastic Oscillator 52.63 0.00

Price Performance

Historical Comparison
ELUT
PPCB

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: